This database contains 63 studies, archived under the term: "Canada"
Click here to filter this large number of results.
Electronic organiser and Alzheimer’s disease: fact or fiction?
Imbeault, Hélène,
Bier, Nathalie,
Pigot, Hélène,
Gagnon, Lise,
Marcotte, Nicolas,
Fulop, Tamas,
Giroux, Sylvain
Alzheimer’s disease is a degenerative disease characterised by a progressive loss of cognitive functions and impairment of activities of daily living severe enough to interfere with normal functioning. To help persons with this disease perform a variety of activities, our research team developed AP@LZ, an electronic organiser specifically designed for them. Two participants with Alzheimer’s […]
Object alternation: a novel probe of medial frontal function in frontotemporal dementia
Freedman, Morris,
Binns, Malcolm A.,
Black, Sandra E.,
Levine, Brian,
Miller, Bruce L.,
Ramirez, Joel,
Szilagyi, Gregory M.,
Scott, Christopher J. M.,
McNeely, Alicia A.,
Stuss, Donald T.
We studied behavioral variant frontotemporal dementia (bvFTD) using object alternation (OA) as a novel probe of cognition. This task was adopted from animal models and is sensitive to ventrolateral-orbitofrontal and medial frontal function in humans. OA was administered to bvFTD patients, normal controls, and a dementia control group with Alzheimer disease (AD). Two other frontal […]
Oxytocin for frontotemporal dementia: A randomized dose-finding study of safety and tolerability
Finger, E. C.,
MacKinley, J.,
Blair, M.,
Oliver, L. D.,
Jesso, S.,
Tartaglia, M. C.,
Borrie, M.,
Wells, J.,
Dziobek, I.,
Pasternak, S.,
Mitchell, D. G. V.,
Rankin, K.,
Kertesz, A.,
Boxer, A.
Objective: To determine the safety and tolerability of 3 doses of intranasal oxytocin (Syntocinon; Novartis, Bern, Switzerland) administered to patients with frontotemporal dementia (FTD). Methods: We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible doses of intranasal oxytocin (24, 48, or 72 IU) administered twice daily for […]
Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study
Emre, Murat,
Poewe, Werner,
De Deyn, Peter Paul,
Barone, Paolo,
Kulisevsky, Jaime,
Pourcher, Emmanuelle,
van Laar, Teus,
Storch, Alexander,
Micheli, Federico,
Burn, David,
Durif, Frank,
Pahwa, Rajesh,
Callegari, Francesca,
Tenenbaum, Nadia,
Strohmaier, Christine
Objective: This study investigated the long-term safety of rivastigmine (12 mg/d capsules, 9.5 mg/24 h patch) and effects on motor symptoms in patients with mild-to-moderately severe Parkinson disease dementia.; Methods: This was a 76-week, prospective, open-label, randomized study in patients aged 50 to 85 years. Primary outcomes included incidence of, and discontinuation due to, predefined […]
“Learning to become a family caregiver” efficacy of an intervention program for caregivers following diagnosis of dementia in a relative
Ducharme, F. C.,
Levesque, L. L.,
Lachance, L. M.,
Kergoat, M.-J.,
Legault, A. J.,
Beaudet, L. M.,
Zarit, S. H.
Purpose: The purpose of this experimental study was to test the efficacy of a psychoeducational individual program conceived to facilitate transition to the caregiver role following diagnosis of Alzheimer disease in a relative.; Design and Methods: Caregivers were recruited in memory clinics and randomized to an experimental group (n = 62) or a control group […]
Predicting decline in mild cognitive impairment: A prospective cognitive study
Objective: The primary aim of this study was to identify cognitive tests that differentiate between persons with mild cognitive impairment (MCI) who later develop cognitive decline and those who remain stable. Method: This study used a prospective longitudinal design. One hundred twenty-two older adults with single-domain or multiple-domain amnestic MCI were recruited from memory clinics. […]